SGLT2 inhibitors: towards a personalized prescription

Jean-Baptiste de Freminville^{1

2

3}, Theodora Bejan-Angoulvant^{2

3

4}

Affiliations

¹ Cardiology Department, CHRU Tours, 37044 Tours Cedex 9, France.
² Faculty of Medicine, University of Tours, 37044 Tours Cedex 9, France.
³ INSERM, UMR 1327, ISCHEMIA 'Membrane Signaling and Inflammation in Reperfusion Injuries', 37044 Tours Cedex 9, France.
⁴ Medical Pharmacology Department, CHRU de Tours, 37044 Tours Cedex 9, France.

Editorial

Jean-Baptiste de Freminville et al. Eur J Prev Cardiol. 2026.

. 2026 Jan 6;33(1):99-100.

doi: 10.1093/eurjpc/zwaf220.

Jean-Baptiste de Freminville^{1

2

3}, Theodora Bejan-Angoulvant^{2

3

4}

¹ Cardiology Department, CHRU Tours, 37044 Tours Cedex 9, France.
² Faculty of Medicine, University of Tours, 37044 Tours Cedex 9, France.
³ INSERM, UMR 1327, ISCHEMIA 'Membrane Signaling and Inflammation in Reperfusion Injuries', 37044 Tours Cedex 9, France.
⁴ Medical Pharmacology Department, CHRU de Tours, 37044 Tours Cedex 9, France.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

Effect of sodium-glucose cotransporter-2 inhibitors on kidney outcomes of individuals with type 2 diabetes according to blood pressure levels.
Jimba T, Kaneko H, Suzuki Y, Okada A, Azegami T, Ko T, Fujiu K, Morita H, Takeda N, Hayashi K, Yokoo T, Node K, Komuro I, Yasunaga H, Nangaku M, Takeda N. Jimba T, et al. Eur J Prev Cardiol. 2026 Jan 6;33(1):91-98. doi: 10.1093/eurjpc/zwaf156. Eur J Prev Cardiol. 2026. PMID: 40100750